These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22439785)

  • 1. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2008 Aug; 5(4):346-57. PubMed ID: 18690832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
    Becker RE; Greig NH
    Alzheimers Dement; 2013 Jan; 9(1):50-7. PubMed ID: 22465172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches.
    González JF; Alcántara AR; Doadrio AL; Sánchez-Montero JM
    Expert Opin Drug Discov; 2019 Sep; 14(9):879-891. PubMed ID: 31165654
    [No Abstract]   [Full Text] [Related]  

  • 6. Why so few drugs for Alzheimer's disease? Are methods failing drugs?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2010 Nov; 7(7):642-51. PubMed ID: 20704560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Future of Alzheimer's Therapy with the Best Approach.
    Singh H; Chawla V; Bala R; Dureja H
    CNS Neurol Disord Drug Targets; 2020; 19(9):691-697. PubMed ID: 32351189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments with tau-based drug discovery.
    Iqbal K; Liu F; Gong CX
    Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease.
    Padhi D; Govindaraju T
    J Med Chem; 2022 May; 65(10):7088-7105. PubMed ID: 35559617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
    Bachurin SO; Bovina EV; Ustyugov AA
    Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications.
    Sabbagh JJ; Kinney JW; Cummings JL
    Neurobiol Aging; 2013 Jan; 34(1):169-83. PubMed ID: 22464953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
    Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
    Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
    Carlsson CM
    J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update.
    Bales KR
    Expert Opin Drug Discov; 2012 Apr; 7(4):281-97. PubMed ID: 22458501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aβ regulation-based multitarget strategy for drug discovery against Alzheimer's disease.
    Guo X; Jiang W; Li C; Zhu Z; Shen X
    Rev Neurosci; 2015; 26(1):13-30. PubMed ID: 25720054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical trials in Alzheimer's disease: selection and evaluation of drug candidates.
    Reines SA
    Prog Clin Biol Res; 1989; 317():1283-90. PubMed ID: 2690095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.